RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mendus AB (publ) - Stock

Mendus AB (publ) Net Income 2024

Mendus AB (publ) Net Income

-122.42 M SEK

Ticker

IMMU.ST

ISIN

SE0005003654

WKN

A1W59F

In 2024, Mendus AB (publ)'s profit amounted to -122.42 M SEK, a 20.47% increase from the -101.62 M SEK profit recorded in the previous year.

The Mendus AB (publ) Net Income history

YEARNET INCOME (undefined SEK)
2026e-49.06
2025e51.37
2024e-122.42
2023-101.62
2022-138.79
2021-133.41
2020-89.25
2019-47.77
2018-97.86
2017-80.34
2016-36.79
2015-43.92
2014-35.61
2013-16.18
2012-6.89
2011-4.24
2010-2.67
2009-2.29
2008-1.42
2007-0.36

Mendus AB (publ) Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mendus AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mendus AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mendus AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mendus AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mendus AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mendus AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mendus AB (publ)’s growth potential.

Mendus AB (publ) Revenue, EBIT and net profit per share

DateMendus AB (publ) RevenueMendus AB (publ) EBITMendus AB (publ) Net Income
2026e0 undefined-66.81 M undefined-49.06 M undefined
2025e179.52 M undefined48.3 M undefined51.37 M undefined
2024e1.04 M undefined-130.3 M undefined-122.42 M undefined
20230 undefined-101.77 M undefined-101.62 M undefined
20221.79 M undefined-133.68 M undefined-138.79 M undefined
20210 undefined-129.28 M undefined-133.41 M undefined
20200 undefined-86.03 M undefined-89.25 M undefined
20190 undefined-44.86 M undefined-47.77 M undefined
20180 undefined-97.85 M undefined-97.86 M undefined
20170 undefined-80.7 M undefined-80.34 M undefined
20160 undefined-36.74 M undefined-36.79 M undefined
20150 undefined-43.64 M undefined-43.92 M undefined
20140 undefined-36.4 M undefined-35.61 M undefined
20130 undefined-16.65 M undefined-16.18 M undefined
20120 undefined-6.97 M undefined-6.89 M undefined
201110,000 undefined-4.31 M undefined-4.24 M undefined
20100 undefined-2.71 M undefined-2.67 M undefined
20090 undefined-2.31 M undefined-2.29 M undefined
20080 undefined-1.52 M undefined-1.42 M undefined
20070 undefined-360,000 undefined-360,000 undefined

Mendus AB (publ) stock margins

The Mendus AB (publ) margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mendus AB (publ). The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mendus AB (publ).

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mendus AB (publ)'s sales revenue. A higher gross margin percentage indicates that the Mendus AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mendus AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mendus AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mendus AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mendus AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mendus AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mendus AB (publ) Margin History

Mendus AB (publ) Gross marginMendus AB (publ) Profit marginMendus AB (publ) EBIT marginMendus AB (publ) Profit margin
2026e167.22 %0 %0 %
2025e167.22 %26.91 %28.61 %
2024e167.22 %-12,517.13 %-11,760.23 %
2023167.22 %0 %0 %
2022167.22 %-7,451.73 %-7,736.07 %
2021167.22 %0 %0 %
2020167.22 %0 %0 %
2019167.22 %0 %0 %
2018167.22 %0 %0 %
2017167.22 %0 %0 %
2016167.22 %0 %0 %
2015167.22 %0 %0 %
2014167.22 %0 %0 %
2013167.22 %0 %0 %
2012167.22 %0 %0 %
2011167.22 %-43,100 %-42,400 %
2010167.22 %0 %0 %
2009167.22 %0 %0 %
2008167.22 %0 %0 %
2007167.22 %0 %0 %

Mendus AB (publ) Aktienanalyse

What does Mendus AB (publ) do?

Immunicum AB is a biopharmaceutical company based in Stockholm, Sweden. It was founded in 2002 and has been working on developing innovative cancer therapies. The company aims to fight cancer cells in the body by targeting the activation of the body's immune system. Immunicum's business model is based on developing therapies that utilize allogeneic cell therapy. This involves using cells from donors to support specific processes in the body. Immunicum focuses on using dendritic cells as a model to specifically activate the body's immune system and fight cancer cells. The company has various divisions involved in the value chain of cancer therapy. One important area is the research and development of immunotherapies based on allogeneic cell therapy. Dendritic cells in particular are studied and further developed to enhance their effectiveness in fighting cancer. Another important division of Immunicum is clinical development, which involves conducting clinical trials to test and demonstrate the efficacy of the developed therapies in controlled studies. The results can then be used to seek approval for the therapies from regulatory authorities. Commercial development is another crucial area for Immunicum, involving the marketing and sale of the developed therapies. The company works closely with partners in the pharmaceutical industry to distribute the therapies worldwide and make them accessible to patients. Currently, the key product of Immunicum is the medication ilixadencel, which is a therapy based on allogeneic cell therapy that activates dendritic cells. Ilixadencel is being developed and tested as a treatment option for patients with renal cell carcinoma and glioblastoma. The medication is currently in clinical development and has already shown promising results in early studies. In addition to ilixadencel, Immunicum is also working on other products developed based on allogeneic cell therapy. This includes therapies for other types of cancer such as liver cancer and pancreatic cancer. The company has also achieved promising results in this area. Overall, Immunicum is an innovative biotech company aiming to develop new and effective cancer therapies. By specifically activating the body's immune system, their goal is to fight cancer cells and improve the quality of life for patients. The company has already made promising developments in this field and continues to work on improving the effectiveness of its therapies. Mendus AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Mendus AB (publ)'s Profit Margins

The profit margins of Mendus AB (publ) represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Mendus AB (publ)'s financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Mendus AB (publ)'s profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Mendus AB (publ)'s profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Mendus AB (publ)’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Mendus AB (publ) Stock

How much profit has Mendus AB (publ) made this year?

Mendus AB (publ) has made -122.42 M SEK this year.

How has the profit developed compared to last year?

The profit has increased by 20.47% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Mendus AB (publ) publish its earnings?

Mendus AB (publ) publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Mendus AB (publ)?

The profits of Mendus AB (publ) are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Mendus AB (publ)?

You can learn more about the earnings of Mendus AB (publ) by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Mendus AB (publ) pay?

Over the past 12 months, Mendus AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mendus AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Mendus AB (publ)?

The current dividend yield of Mendus AB (publ) is .

When does Mendus AB (publ) pay dividends?

Mendus AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mendus AB (publ)?

Mendus AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Mendus AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mendus AB (publ) located?

Mendus AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mendus AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mendus AB (publ) from 7/2/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Mendus AB (publ) pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Mendus AB (publ) in the year 2023?

In the year 2023, Mendus AB (publ) distributed 0 SEK as dividends.

In which currency does Mendus AB (publ) pay out the dividend?

The dividends of Mendus AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mendus AB (publ)

Our stock analysis for Mendus AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mendus AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.